The alarmin IL-33 promotes regulatory T-cell function in the intestine

Chris Schiering, Thomas Krausgruber, Agnieszka Chomka, Anja Fröhlich, Krista Adelmann, Elizabeth A Wohlfert, Johanna Pott, Thibault Griseri, Julia Bollrath, Ahmed N Hegazy, Oliver J Harrison, Benjamin M J Owens, Max Löhning, Yasmine Belkaid, Padraic G Fallon, Fiona Powrie, Chris Schiering, Thomas Krausgruber, Agnieszka Chomka, Anja Fröhlich, Krista Adelmann, Elizabeth A Wohlfert, Johanna Pott, Thibault Griseri, Julia Bollrath, Ahmed N Hegazy, Oliver J Harrison, Benjamin M J Owens, Max Löhning, Yasmine Belkaid, Padraic G Fallon, Fiona Powrie

Abstract

FOXP3(+) regulatory T cells (Treg cells) are abundant in the intestine, where they prevent dysregulated inflammatory responses to self and environmental stimuli. It is now appreciated that Treg cells acquire tissue-specific adaptations that facilitate their survival and function; however, key host factors controlling the Treg response in the intestine are poorly understood. The interleukin (IL)-1 family member IL-33 is constitutively expressed in epithelial cells at barrier sites, where it functions as an endogenous danger signal, or alarmin, in response to tissue damage. Recent studies in humans have described high levels of IL-33 in inflamed lesions of inflammatory bowel disease patients, suggesting a role for this cytokine in disease pathogenesis. In the intestine, both protective and pathological roles for IL-33 have been described in murine models of acute colitis, but its contribution to chronic inflammation remains ill defined. Here we show in mice that the IL-33 receptor ST2 is preferentially expressed on colonic Treg cells, where it promotes Treg function and adaptation to the inflammatory environment. IL-33 signalling in T cells stimulates Treg responses in several ways. First, it enhances transforming growth factor (TGF)-β1-mediated differentiation of Treg cells and, second, it provides a necessary signal for Treg-cell accumulation and maintenance in inflamed tissues. Strikingly, IL-23, a key pro-inflammatory cytokine in the pathogenesis of inflammatory bowel disease, restrained Treg responses through inhibition of IL-33 responsiveness. These results demonstrate a hitherto unrecognized link between an endogenous mediator of tissue damage and a major anti-inflammatory pathway, and suggest that the balance between IL-33 and IL-23 may be a key controller of intestinal immune responses.

Figures

Figure 1. ST2-expressing T reg cells are…
Figure 1. ST2-expressing Treg cells are enriched in the colon
a, Change in gene expression in cTreg cells vs. MLN Treg cells (n=3 per group) presented as volcano plot. b, Top differentially upregulated transcripts in cTreg vs. MLN Treg cells. c, ST2 protein expression on Treg cells from indicated organs. d, Phenotypic analysis of ST2− or ST2+ cTreg cells. e, Expression of transcription factors in cTreg cells. f, Representative histograms gated on cTreg cells from control or Gata3f/f-Foxp3-Cre mice.
Figure 2. Effects of IL-33 on iT…
Figure 2. Effects of IL-33 on iTreg and tTreg cells
a, Naïve CD4+ T cells were cultured with anti-CD3/CD28 plus indicated cytokines and the frequencies and absolute numbers of Foxp3+ T cells determined 3 days later (mean ± s.e.m. of three independent experiments). b, Naïve CD4+ T cells were cultured for 48h with anti-CD3/CD28 plus TGF-β1 followed by stimulation with IL-33 for 45 minutes. Blots are representative of two independent experiments. c-d, Cells were cultured and stimulated as in (b) and recruitment of GATA3 or RNA polymerase II (Pol II) to the indicated regions assessed by ChIP-qPCR. Data are from one experiment representative of two (mean ± s.d.). e, Representative plots of Treg cells cultured with anti-CD3/CD28 plus indicated cytokines and analyzed after 3 days. Data are representative of three independent experiments. f, Treg cells were cultured with anti-CD3/CD28 for 24h followed by stimulation with IL-33. Blots are representative of three independent experiments. g, Mixed chimaeras were generated containing WT and St2−/− bone marrow cells. Reconstituted mice were analyzed at steady state or two weeks after infection with Helicobacter hepaticus and anti-IL-10R treatment (inflamed). Absolute numbers of WT or St2−/− Treg cells in steady state (n = 3) and inflamed (n = 6) hosts (mean ± s.e.m). h, Analysis of Foxp3 expression in Treg cells from inflamed chimaeric hosts presented as geometric mean fluorescence intensity (gMFI). *P<0.05, **P<0.01 *** P<0.001 as calculated by 1way-ANOVA with Bonferroni post-test or paired Students’ t-test.
Figure 3. IL-33 promotes T reg cell…
Figure 3. IL-33 promotes Treg cell stability and function in vivo
a, C57BL/6 Rag1−/− mice were injected with CD45.1+ naïve T cells alone (RBhi, n = 4) or in combination with WT (n = 4) or St2−/− (n = 6) CD45.1− Treg cells. Mice were sacrificed after 6-8 weeks post transfer and colitis scores are shown. b, Absolute numbers of colon lamina propria (LP) cells from mice in (a). c, C57BL/6 Rag1−/− mice were injected as in (a) and sacrificed at 2 weeks post injection. Representative plots are gated on colonic Treg cell progeny (CD45.1−). d, Ratio of RBhi T cell progeny (CD45.1+) to WT or St2−/− Foxp3+ Treg cell progeny (CD45.1−) in the colon (n = 5 per group) from mice in (c), (mean ± s.e.m). e, C57BL/6 Rag1−/− mice were injected as in (a) and sacrificed at 8 weeks post injection. Representative plots are gated on colonic Treg cell progeny (CD45.1−). f, Ratio of RBhi T cell progeny (CD45.1+) to WT or St2−/− Treg cell progeny (CD45.1−) in the colon from mice in (e), (mean ± s.e.m). g, Absolute numbers of RBhi T cell progeny (CD45.1+) in the colon from mice in (e), (mean ± s.e.m). h, Analysis of Foxp3 expression in colonic Foxp3+CD45.1− Treg cells presented as gMFI (mean ± s.e.m). Results are representative of two independent experiments. *P<0.05 **P<0.01 *** P<0.001 **** P<0.0001 as calculated by 1way-ANOVA with Bonferroni post-test or Students’ t-test.
Figure 4. IL-23 inhibits the effects of…
Figure 4. IL-23 inhibits the effects of IL-33 on Treg cells
a, Naïve CD4+ T cells were cultured with anti-CD3/CD28 plus TGF-β1 as well as indicated cytokines and the frequencies of Foxp3+ T cells determined after 3 days later (mean ± s.e.m. of three independent experiments). b, Naïve CD4+ T cells were cultured with anti-CD3/CD28 plus indicated cytokines for 48h. Data are from one experiment representative of two (mean ± s.d.). c, Naïve CD4+ T cells were cultured as indicated. Representative blots of two independent experiments are shown. d, C57BL/6 Il23a−/−Rag1−/− mice were injected with CD45RBhi WT (n = 9) or St2−/− (n = 10) T cells. Mice were sacrificed after 6-8 weeks post transfer and frequencies of Foxp3+CD4+ T cells in colon are shown. e, Colitis scores for mice in (d). f, Expression of indicated cytokines by colonic CD4+ T cells from mice in (d). g, Treg cells were cultured with anti-CD3/CD28 for 24h followed by stimulation with IL-33 in the presence or absence of IL-23. Representative blots of two independent experiments are shown. h, Treg cells were cultured in the presence of anti-CD3/CD28 for 24h and mRNA expression of indicated genes measured following stimulation with IL-33 for 45 minutes in the presence or absence of IL-23 (mean ± s.e.m. of three independent experiments). i, Treg cells were cultured with anti-CD3/CD28 for 24h and representative blots of two independent experiments are shown. *P<0.05, **P<0.01 *** P<0.001 as calculated by 1way-ANOVA with Bonferroni post-test or Students’ t-test.

References

    1. Burzyn D, Benoist C, Mathis D. Regulatory T cells in nonlymphoid tissues. Nature immunology. 2013;14:1007–1013.
    1. Pichery M, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. Journal of immunology. 2012;188:3488–3495.
    1. Palmer G, Gabay C. Interleukin-33 biology with potential insights into human diseases. Nature reviews. Rheumatology. 2011;7:321–329.
    1. Beltran CJ, et al. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflammatory bowel diseases. 2010;16:1097–1107.
    1. Kobori A, et al. Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitis. J Gastroenterol. 2010;45:999–1007.
    1. Pastorelli L, et al. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:8017–8022.
    1. Seidelin JB, et al. IL-33 is upregulated in colonocytes of ulcerative colitis. Immunol Lett. 2010;128:80–85.
    1. Oboki K, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proceedings of the National Academy of Sciences of the United States of America. 2010;107:18581–18586.
    1. Duan L, et al. Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Molecular medicine. 2012;18:753–761.
    1. Grobeta P, Doser K, Falk W, Obermeier F, Hofmann C. IL-33 attenuates development and perpetuation of chronic intestinal inflammation. Inflammatory bowel diseases. 2012;18:1900–1909.
    1. Sedhom MA, et al. Neutralisation of the interleukin-33/ST2 pathway ameliorates experimental colitis through enhancement of mucosal healing in mice. Gut. 2013;62:1714–1723.
    1. Schmitz J, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–490.
    1. Thornton AM, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. Journal of immunology. 2010;184:3433–3441.
    1. Wang Y, Su MA, Wan YY. An essential role of the transcription factor GATA-3 for the function of regulatory T cells. Immunity. 2011;35:337–348.
    1. Wohlfert EA, et al. GATA3 controls Foxp3(+) regulatory T cell fate during inflammation in mice. J Clin Invest. 2011;121:4503–4515.
    1. Rudra D, et al. Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nature immunology. 2012;13:1010–1019.
    1. Guo L, et al. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:13463–13468.
    1. Maneechotesuwan K, et al. Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3. Journal of immunology. 2007;178:2491–2498.
    1. Furusawa JI, et al. Critical Role of p38 and GATA3 in Natural Helper Cell Function. Journal of immunology. 2013;191:1818–1826.
    1. Turnquist HR, et al. IL-33 expands suppressive CD11b+ Gr-1(int) and regulatory T cells, including ST2L+ Foxp3+ cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. Journal of immunology. 2011;187:4598–4610.
    1. Wasserman A, et al. Interleukin-33 augments Treg cell levels: a flaw mechanism in atherosclerosis. The Israel Medical Association journal: IMAJ. 2012;14:620–623.
    1. Kullberg MC, et al. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. The Journal of experimental medicine. 2006;203:2485–2494.
    1. Hayakawa H, Hayakawa M, Kume A, Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. The Journal of biological chemistry. 2007;282:26369–26380.
    1. Diaz-Jimenez D, et al. Soluble ST2: a new and promising activity marker in ulcerative colitis. World journal of gastroenterology: WJG. 2011;17:2181–2190.
    1. Zheng Y, et al. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature. 2010;463:808–812.
    1. Wan YY, Flavell RA. Regulatory T-cell functions are subverted and converted owing to attenuated Foxp3 expression. Nature. 2007;445:766–770.
    1. Kitoh A, et al. Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells. Immunity. 2009;31:609–620.
    1. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011;474:298–306.
    1. Izcue A, et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity. 2008;28:559–570.
    1. Ahern PP, et al. Interleukin-23 drives intestinal inflammation through direct activity on T cells. Immunity. 2010;33:279–288.
    1. Fontenot JD, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22:329–341.
    1. Bettelli E, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–238.
    1. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. The Journal of experimental medicine. 2000;192:295–302.
    1. Izcue A, et al. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity. 2008;28:559–570.
    1. Uhlig HH, et al. Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. Journal of immunology. 2006;177:5852–5860.
    1. Hue S, et al. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. The Journal of experimental medicine. 2006;203:2473–2483.
    1. Rudra D, et al. Transcription factor Foxp3 and its protein partners form a complex regulatory network. Nature immunology. 2012;13:1010–1019.
    1. Krausgruber T, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nature immunology. 2011;12:231–238.

Source: PubMed

3
S'abonner